<DOC>
	<DOCNO>NCT01488162</DOCNO>
	<brief_summary>This multi-center , prospective , observational study describe management relapse refractory chronic lymphocytic leukemia ( CLL ) patient . Data collect 2 year .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Patients With Relapsing Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis relapse refractory chronic lymphocytic leukemia ( CLL ) first second relapse Previous treatment MabThera/Rituxan MabThera/Rituxan treatment plan current relapse Richter syndrome Life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>